Human Milk Oligosaccharides

The HMO ingredient market sits at $0.35–0.4 billion today, on a path to ~$0.7B (base case) by 2031. The bigger story is what's happening inside it: a Chinese cost cohort closing on Western incumbents at a pace that will reset commodity 2'-FL prices, an IP cliff arriving on a published schedule, and value migrating off the molecule into complexity, claims and qualified supply relationships.

This report develops each of those threads at unprecedented depth. Twelve chapters and six appendices, 38+ named exhibits, 100+ public-record citations. Supply and capacity is read plant-by-plant. The cost stack is built bottom-up with every modelling assumption stated. The IP and patent landscape is read as a maintenance-fee schedule with named expiries through 2042. Regulatory access is named structure × jurisdiction × player across EU, US, China, India, SE-Asia and AU-NZ. Health evidence is graded trial-by-trial against EFSA-grade substantiation standards. The forward call is named, dated and falsifiable. The contents page that follows is the proof-point.

Authored by an operator with twenty years across the bio-based economy — global business-development leadership at DuPont Industrial Biosciences, CCO and CEO roles at specialty biotechs (including HMO), with transformation and exit; PhD and London Business School sustainability certification.

For operators evaluating their position, investors evaluating the category, and advisors who need a defensible read at depth.

Decisive specific numbers — the Chinese commodity cost floor, the bear / bull 2031 forecasts, the disclosed Chinese capacity, the post-2030 IP-cliff dates — are blanked in this sample. They sit in the purchased report.